CervoMed (CRVO) Projected to Post Earnings on Friday

CervoMed (NASDAQ:CRVO - Get Free Report) is anticipated to announce its earnings results before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $1.79 million for the quarter.

CervoMed (NASDAQ:CRVO - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.13). CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. The business had revenue of $2.16 million during the quarter, compared to the consensus estimate of $1.51 million. On average, analysts expect CervoMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CervoMed Stock Performance

Shares of NASDAQ:CRVO traded down $0.16 during trading hours on Friday, hitting $11.08. 1,246,781 shares of the company's stock traded hands, compared to its average volume of 1,286,409. The company's fifty day simple moving average is $4.88 and its two-hundred day simple moving average is $7.34. CervoMed has a 52 week low of $1.80 and a 52 week high of $25.92. The company has a market cap of $96.43 million, a price-to-earnings ratio of -5.46 and a beta of 0.21.

Analysts Set New Price Targets

Several research firms have issued reports on CRVO. Canaccord Genuity Group lifted their price target on shares of CervoMed from $12.00 to $21.00 and gave the stock a "buy" rating in a research report on Tuesday, March 18th. Brookline Capital Management upgraded CervoMed from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 11th. Chardan Capital raised CervoMed from a "neutral" rating to a "buy" rating and set a $14.00 target price for the company in a report on Thursday, March 13th. D. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of CervoMed in a research note on Wednesday, March 26th. Finally, HC Wainwright downgraded CervoMed from a "buy" rating to a "neutral" rating in a report on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $27.50.

Remove Ads

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.